Molten Ventures led the Series A round to support product development and international expansion.
"We are seeing huge demand from manufacturers looking for solutions to help them transform their operations in the face of increasing pressures and a worsening skills gap."
Molten Ventures led the Series B round with participation from Altair and existing investors to accelerate the development of Deltaflow.OS.
"Solving quantum error correction – one of the defining scientific challenges of our times – will enable quantum computers to accurately simulate the true complexity of nature. Armed with useful quantum computers, humans will enter the Quantum Age, where we go from slow trial and error to solve complex problems to an era of rapid design using quantum computers. We haven’t even begun to imagine the many ways such technology will positively transform our world."
The additional financing was backed by Ericsson Ventures, Metrea Discovery, VU Venture Partners, Sanctor Capital, and Tirta Ventures.
"We are thrilled to have the support of such a diverse and experienced group of investors. This additional funding will enable us to continue the significant progress we have made off the back of our Series A and expedite the advancement of our cloud-based solutions for the metaverse. Our objective is to bridge physical and virtual worlds to improve decision-making, support the creator economy and, ultimately, enhance the quality of life in the real world. We believe that the metaverse’s true success and widespread adoption depend on the creators’ ability to build their own experiences at scale, using open and robust metaverse-as-a-service technologies."
The oversubscribed round included backing from Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence.
"This substantial investment round demonstrates continued confidence in the progress of our technical development and its potential to revolutionise the accessibility of gene synthesis. Evonetix is in a very exciting phase, having recently opened our early access program. This investment will support us as we execute on our commercial strategy to put benchtop gene synthesis in the hands of users."
Molten Ventures led the $7m round to support product development and international expansion.
"We’re deeply grateful to our investors whose commitment has enabled Apperio to think differently about this enduring problem of transparency in the business of law"